Product Code: ETC6186091 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | Author: Bhawna Singh | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
The Australian Neural Pain Treatment Market is growing due to the increasing prevalence of chronic pain conditions, including neuropathic pain, that are not adequately addressed by conventional pain management therapies. Neural pain treatments, such as neurostimulation therapies, are emerging as alternatives for patients with conditions like diabetic neuropathy and post-surgical pain. Advances in neuromodulation techniques, including spinal cord stimulation and deep brain stimulation, are enhancing treatment efficacy. The market is further supported by rising awareness of neurological conditions and growing investment in pain management research.
The neural pain treatment market in Australia is expanding due to the rising number of individuals suffering from chronic pain conditions such as neuropathic pain, fibromyalgia, and post-surgical pain. With an aging population and growing awareness of alternative pain management options, treatments like neurostimulation and neuromodulation are seeing greater adoption. Advances in minimally invasive therapies, such as transcranial magnetic stimulation (TMS) and spinal cord stimulation, are helping to address the limitations of traditional pain management methods. However, cost and accessibility of these treatments remain key challenges in the market.
The neural pain treatment market in Australia encounters challenges in terms of patient variability and the complexity of pain management. Developing treatments that can effectively address the diverse causes of neural pain, such as neuropathy or post-surgical pain, remains a significant hurdle. Moreover, there is ongoing debate around the long-term safety of certain treatments, including opioids and invasive procedures, making it difficult to strike a balance between effectiveness and patient well-being.
Investment in neural pain treatment in Australia is driven by the growing prevalence of chronic pain conditions and an aging demographic. The market is transitioning from opioid reliance to alternative therapies like neuromodulation and targeted pharmaceuticals. Investors can explore opportunities in advanced pain management clinics, telehealth platforms offering neural pain therapies, and partnerships with pharmaceutical firms developing non-opioid analgesics.
Government policies in Australia regarding healthcare reimbursement and regulatory approval processes have a significant impact on the neural pain treatment market. The Australian government, through the Pharmaceutical Benefits Scheme (PBS), facilitates patient access to approved pain management therapies, which include neural pain treatments. Research and development grants and funding from organizations like the National Health and Medical Research Council (NHMRC) have accelerated advancements in neural pain therapies. Additionally, policies aimed at improving mental health care also contribute to the growing demand for treatments addressing chronic pain, a common symptom in neurodegenerative conditions.
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Australia Neural Pain Treatment Market Overview |
3.1 Australia Country Macro Economic Indicators |
3.2 Australia Neural Pain Treatment Market Revenues & Volume, 2021 & 2031F |
3.3 Australia Neural Pain Treatment Market - Industry Life Cycle |
3.4 Australia Neural Pain Treatment Market - Porter's Five Forces |
3.5 Australia Neural Pain Treatment Market Revenues & Volume Share, By Type, 2021 & 2031F |
3.6 Australia Neural Pain Treatment Market Revenues & Volume Share, By Causes, 2021 & 2031F |
3.7 Australia Neural Pain Treatment Market Revenues & Volume Share, By Treatment, 2021 & 2031F |
3.8 Australia Neural Pain Treatment Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.9 Australia Neural Pain Treatment Market Revenues & Volume Share, By End User, 2021 & 2031F |
3.10 Australia Neural Pain Treatment Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 Australia Neural Pain Treatment Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of neural pain conditions in Australia |
4.2.2 Growing aging population leading to higher demand for neural pain treatments |
4.2.3 Advancements in medical technology and treatment options for neural pain |
4.3 Market Restraints |
4.3.1 Stringent regulatory approvals for neural pain treatment products |
4.3.2 High cost associated with advanced neural pain treatments |
4.3.3 Limited awareness among patients and healthcare professionals about newer treatment options |
5 Australia Neural Pain Treatment Market Trends |
6 Australia Neural Pain Treatment Market, By Types |
6.1 Australia Neural Pain Treatment Market, By Type |
6.1.1 Overview and Analysis |
6.1.2 Australia Neural Pain Treatment Market Revenues & Volume, By Type, 2021- 2031F |
6.1.3 Australia Neural Pain Treatment Market Revenues & Volume, By Postherpetic, 2021- 2031F |
6.1.4 Australia Neural Pain Treatment Market Revenues & Volume, By Trigeminal, 2021- 2031F |
6.1.5 Australia Neural Pain Treatment Market Revenues & Volume, By Glossopharyngeal, 2021- 2031F |
6.1.6 Australia Neural Pain Treatment Market Revenues & Volume, By Occipital, 2021- 2031F |
6.1.7 Australia Neural Pain Treatment Market Revenues & Volume, By Peripheral, 2021- 2031F |
6.1.8 Australia Neural Pain Treatment Market Revenues & Volume, By Intercostal, 2021- 2031F |
6.2 Australia Neural Pain Treatment Market, By Causes |
6.2.1 Overview and Analysis |
6.2.2 Australia Neural Pain Treatment Market Revenues & Volume, By Infection, 2021- 2031F |
6.2.3 Australia Neural Pain Treatment Market Revenues & Volume, By Multiple Sclerosis, 2021- 2031F |
6.2.4 Australia Neural Pain Treatment Market Revenues & Volume, By Nerve Pressure, 2021- 2031F |
6.2.5 Australia Neural Pain Treatment Market Revenues & Volume, By Diabetes, 2021- 2031F |
6.2.6 Australia Neural Pain Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Australia Neural Pain Treatment Market, By Treatment |
6.3.1 Overview and Analysis |
6.3.2 Australia Neural Pain Treatment Market Revenues & Volume, By Medication, 2021- 2031F |
6.3.3 Australia Neural Pain Treatment Market Revenues & Volume, By Surgery, 2021- 2031F |
6.3.4 Australia Neural Pain Treatment Market Revenues & Volume, By Physical Therapy, 2021- 2031F |
6.3.5 Australia Neural Pain Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Australia Neural Pain Treatment Market, By Route of Administration |
6.4.1 Overview and Analysis |
6.4.2 Australia Neural Pain Treatment Market Revenues & Volume, By Oral, 2021- 2031F |
6.4.3 Australia Neural Pain Treatment Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.4.4 Australia Neural Pain Treatment Market Revenues & Volume, By Topical, 2021- 2031F |
6.4.5 Australia Neural Pain Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Australia Neural Pain Treatment Market, By End User |
6.5.1 Overview and Analysis |
6.5.2 Australia Neural Pain Treatment Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.5.3 Australia Neural Pain Treatment Market Revenues & Volume, By Homecare, 2021- 2031F |
6.5.4 Australia Neural Pain Treatment Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
6.5.5 Australia Neural Pain Treatment Market Revenues & Volume, By Others, 2021- 2031F |
6.6 Australia Neural Pain Treatment Market, By Distribution Channel |
6.6.1 Overview and Analysis |
6.6.2 Australia Neural Pain Treatment Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.6.3 Australia Neural Pain Treatment Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.6.4 Australia Neural Pain Treatment Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 Australia Neural Pain Treatment Market Import-Export Trade Statistics |
7.1 Australia Neural Pain Treatment Market Export to Major Countries |
7.2 Australia Neural Pain Treatment Market Imports from Major Countries |
8 Australia Neural Pain Treatment Market Key Performance Indicators |
8.1 Number of clinical trials and research studies on neural pain treatments in Australia |
8.2 Adoption rate of minimally invasive neural pain treatment procedures |
8.3 Patient satisfaction and improvement in quality of life post neural pain treatment |
9 Australia Neural Pain Treatment Market - Opportunity Assessment |
9.1 Australia Neural Pain Treatment Market Opportunity Assessment, By Type, 2021 & 2031F |
9.2 Australia Neural Pain Treatment Market Opportunity Assessment, By Causes, 2021 & 2031F |
9.3 Australia Neural Pain Treatment Market Opportunity Assessment, By Treatment, 2021 & 2031F |
9.4 Australia Neural Pain Treatment Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.5 Australia Neural Pain Treatment Market Opportunity Assessment, By End User, 2021 & 2031F |
9.6 Australia Neural Pain Treatment Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 Australia Neural Pain Treatment Market - Competitive Landscape |
10.1 Australia Neural Pain Treatment Market Revenue Share, By Companies, 2024 |
10.2 Australia Neural Pain Treatment Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |